Tegacorat clinical trials
Also written GRT6019.
How each study uses tegacorat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tegacorat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses tegacorat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular DystrophyNot yet recruitingPhase 2Grünenthal GmbHNCT07911995Written as Tegacorat
- A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsCompletedPhase 1Grünenthal GmbHNCT07347548Written as GRT6019
- Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019CompletedPhase 1Grünenthal GmbHNCT07479745Written as [14C]GRT6019
- A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male ParticipantsCompletedPhase 1Grünenthal GmbHNCT07317063Written as GRT6019
Codes
What other systems call tegacorat · ClinicalTrials.gg INT018427
- UNII (FDA) X4A75C2AX8TEGACORATConfirmed FDA, Wikidata
- Wikidata Q140529343tegacoratConfirmed FDA, Wikidata
- NCI Thesaurus C223310TegacoratOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X4A75C2AX8 | TEGACORAT | Confirmed FDA, Wikidata |
| Wikidata | Q140529343 | tegacorat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C223310 | Tegacorat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.